Clinical Trials Logo

Cutaneous Metastases clinical trials

View clinical trials related to Cutaneous Metastases.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT05481658 Recruiting - Clinical trials for Cutaneous Metastases

Diphencyprone Plus Immune Checkpoint Inhibition in the Treatment of Cutaneous Metastases

Start date: October 6, 2022
Phase: Phase 1
Study type: Interventional

This is a phase I, open label study employing diphencyprone (DPCP) to characterize gene expression changes of various immune cell and tumor markers in cutaneous metastases treated with topical DPCP twice weekly for 12 weeks in combination with PD-1 or PD-L1 immune checkpoint inhibition (ICI), compared to pre-treatment cutaneous metastases and to describe the adverse events associated with DPCP when administered topically twice weekly for 12 weeks in combination with PD-1 or PD-L1 ICI.